MedTrace Logo

T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer

NCT01376674 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2013-08-16

No results posted yet for this study

Summary

Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner.

In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken at different time points before during and after standard radiotherapy in patients with localised prostate cancer. The overall activity of the T-cell-system as well as tumor-specific T-cell-response are evaluated.

Conditions

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Cihan Gani, M.D. · University Hospital Tuebingen

  • Franziska Eckert, MD · University Hospital Tuebingen

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376674 on ClinicalTrials.gov